# Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

> **NCT06014372** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 55 (estimated)

## Conditions studied

- Colon Cancer
- Neoadjuvant Therapy
- Immunotherapy

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** CAPEOX

## Key facts

- **NCT ID:** NCT06014372
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014372, "Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06014372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*